Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in hematology. The Company lead asset is an oral kinase inhibitor under development for hematologic malignancies. Tuspetinib is being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1/2 expansion trial in patients with relapsed or refractory Acute Myeloid Leukemia. For more information, please visit www.aptose.com.